Literature DB >> 20432460

Shepherding AKT and androgen receptor by Ack1 tyrosine kinase.

Kiran Mahajan1, Nupam P Mahajan.   

Abstract

Ack1 (also known as ACK, TNK2, or activated Cdc42 kinase) is a structurally unique non-receptor tyrosine kinase that is expressed in diverse cell types. It integrates signals from plethora of ligand-activated receptor tyrosine kinases (RTKs), for example, MERTK, EGFR, HER2, PDGFR and insulin receptor to initiate intracellular signaling cascades. Ack1 transduces extracellular signals to cytosolic and nuclear effectors such as the protein kinase AKT/PKB and androgen receptor (AR), to promote cell survival and growth. While tyrosine phosphorylation of AR at Tyr267 regulates androgen-independent recruitment of AR to the androgen-responsive enhancers and transcription of AR target genes to drive prostate cancer progression, phosphorylation of an evolutionarily conserved Tyrosine 176 in the kinase domain of AKT is essential for mitotic progression and positively correlates with breast cancer progression. In contrast to AR and AKT, Ack1-mediated phosphorylation of the tumor suppressor Wwox at Tyr287 lead to rapid Wwox polyubiquitination followed by degradation. Thus, by its ability to promote tumor growth by negatively regulating tumor suppressor such as Wwox and positively regulating pro-survival factors such as AKT and AR, Ack1 is emerging as a critical player in cancer biology. In this review, we discuss recent advances in understanding the physiological functions of Ack1 signaling in normal cells and the consequences of its hyperactivation in various cancers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20432460      PMCID: PMC3953130          DOI: 10.1002/jcp.22162

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  77 in total

1.  Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro.

Authors:  Claudio Festuccia; Giovanni Luca Gravina; Leda Biordi; Sandra D'Ascenzo; Vincenza Dolo; Corrado Ficorella; Enrico Ricevuto; Vincenzo Tombolini
Journal:  Prostate       Date:  2009-10-01       Impact factor: 4.104

2.  Down-regulation of active ACK1 is mediated by association with the E3 ubiquitin ligase Nedd4-2.

Authors:  Wing Chan; Rui Tian; Yeow-Fong Lee; Soon Tuck Sit; Louis Lim; Ed Manser
Journal:  J Biol Chem       Date:  2009-01-14       Impact factor: 5.157

3.  HECT E3 ubiquitin ligase Nedd4-1 ubiquitinates ACK and regulates epidermal growth factor (EGF)-induced degradation of EGF receptor and ACK.

Authors:  Qiong Lin; Jian Wang; Chandra Childress; Marius Sudol; David J Carey; Wannian Yang
Journal:  Mol Cell Biol       Date:  2010-01-19       Impact factor: 4.272

4.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

Authors:  Katherine Stemke-Hale; Ana Maria Gonzalez-Angulo; Ana Lluch; Richard M Neve; Wen-Lin Kuo; Michael Davies; Mark Carey; Zhi Hu; Yinghui Guan; Aysegul Sahin; W Fraser Symmans; Lajos Pusztai; Laura K Nolden; Hugo Horlings; Katrien Berns; Mien-Chie Hung; Marc J van de Vijver; Vicente Valero; Joe W Gray; René Bernards; Gordon B Mills; Bryan T Hennessy
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

5.  Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation.

Authors:  Kiran Mahajan; Domenico Coppola; Sridevi Challa; Bin Fang; Y Ann Chen; Weiwei Zhu; Alexis S Lopez; John Koomen; Robert W Engelman; Charlene Rivera; Rebecca S Muraoka-Cook; Jin Q Cheng; Ernst Schönbrunn; Said M Sebti; H Shelton Earp; Nupam P Mahajan
Journal:  PLoS One       Date:  2010-03-19       Impact factor: 3.240

6.  Nephrocystin-1 interacts directly with Ack1 and is expressed in human collecting duct.

Authors:  Lorraine Eley; Shabbir H Moochhala; Roslyn Simms; Friedhelm Hildebrandt; John A Sayer
Journal:  Biochem Biophys Res Commun       Date:  2008-05-12       Impact factor: 3.575

7.  Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is mediated by Grb2: an analysis of ACK1 effects on Axl signaling.

Authors:  Lin Pao-Chun; Perry M Chan; Wing Chan; Ed Manser
Journal:  J Biol Chem       Date:  2009-10-08       Impact factor: 5.157

8.  Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer.

Authors:  G Gravis; F Bladou; N Salem; A Gonçalves; B Esterni; J Walz; S Bagattini; M Marcy; S Brunelle; P Viens
Journal:  Ann Oncol       Date:  2008-05-07       Impact factor: 32.976

9.  Large-scale structural analysis of the classical human protein tyrosine phosphatome.

Authors:  Alastair J Barr; Emilie Ugochukwu; Wen Hwa Lee; Oliver N F King; Panagis Filippakopoulos; Ivan Alfano; Pavel Savitsky; Nicola A Burgess-Brown; Susanne Müller; Stefan Knapp
Journal:  Cell       Date:  2009-01-23       Impact factor: 41.582

10.  TNK2 preserves epidermal growth factor receptor expression on the cell surface and enhances migration and invasion of human breast cancer cells.

Authors:  Jillian Howlin; Jeanette Rosenkvist; Tommy Andersson
Journal:  Breast Cancer Res       Date:  2008-04-24       Impact factor: 6.466

View more
  39 in total

1.  Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Authors:  Gary E Gallick; Paul G Corn; Amado J Zurita; Sue-Hwa Lin
Journal:  Future Med Chem       Date:  2012-01       Impact factor: 3.808

Review 2.  PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics.

Authors:  Kiran Mahajan; Nupam P Mahajan
Journal:  J Cell Physiol       Date:  2012-09       Impact factor: 6.384

3.  Molecular pathways: targeting the kinase effectors of RHO-family GTPases.

Authors:  Tatiana Y Prudnikova; Sonali J Rawat; Jonathan Chernoff
Journal:  Clin Cancer Res       Date:  2014-10-21       Impact factor: 12.531

4.  ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1.

Authors:  Kiran Mahajan; Harshani R Lawrence; Nicholas J Lawrence; Nupam P Mahajan
Journal:  J Biol Chem       Date:  2014-08-22       Impact factor: 5.157

5.  Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer.

Authors:  Rong Hu; Samuel R Denmeade; Jun Luo
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09

6.  Androgen receptor serine 81 mediates Pin1 interaction and activity.

Authors:  Raffaele La Montagna; Isabella Caligiuri; Pasquale Maranta; Chiara Lucchetti; Luca Esposito; Marco G Paggi; Giuseppe Toffoli; Flavio Rizzolio; Antonio Giordano
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

7.  Alternative signaling pathways from IGF1 or insulin to AKT activation and FOXO1 nuclear efflux in adult skeletal muscle fibers.

Authors:  Sarah J Russell; Martin F Schneider
Journal:  J Biol Chem       Date:  2020-08-31       Impact factor: 5.157

8.  A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitors.

Authors:  Sharangdhar S Phatak; Shuxing Zhang
Journal:  Pac Symp Biocomput       Date:  2013

Review 9.  ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation.

Authors:  Kiran Mahajan; Nupam P Mahajan
Journal:  Cancer Lett       Date:  2013-04-15       Impact factor: 8.679

10.  SIAH ubiquitin ligases target the nonreceptor tyrosine kinase ACK1 for ubiquitinylation and proteasomal degradation.

Authors:  M Buchwald; K Pietschmann; P Brand; A Günther; N P Mahajan; T Heinzel; O H Krämer
Journal:  Oncogene       Date:  2012-12-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.